CSBIO(SZ:300255) Xin Lang Cai Jing·2026-02-04 01:34Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical's stock performance and financing activities indicate a high level of market interest, despite a decline in revenue and profit [1][2]. - On February 3, Changshan Pharmaceutical's stock rose by 3.29%, with a trading volume of 868 million yuan, and a net financing buy of -5.88 million yuan, indicating a high financing balance of 2.508 billion yuan, which is 5.44% of its market capitalization [1]. - The company has a significant portion of its financing balance exceeding the 80th percentile over the past year, suggesting a high level of leverage in the market [1]. Group 2 - As of January 30, the number of shareholders in Changshan Pharmaceutical increased by 0.59% to 41,700, while the average number of circulating shares per person decreased by 0.59% to 22,018 shares [2]. - For the period from January to September 2025, Changshan Pharmaceutical reported a revenue of 681 million yuan, a year-on-year decrease of 13.11%, and a net profit attributable to shareholders of -44.82 million yuan, a decline of 714.77% [2]. - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.595 million yuan distributed in the last three years [3].